# Siemens Healthineers starts carving out its 16-billion-test diagnostics business as Olyrian Diagnostics

By MarketScale Newsroom · Published 2026-11-17 · Healthcare on MarketScale
Canonical: https://www.marketscale.com/industries/healthcare/siemens-healthineers-begins-separating-its-16-billion-test-lab-business-into-olyrian-diagnostics

> Siemens Healthineers has begun carving out its diagnostics unit as Olyrian Diagnostics. It says contracts and service levels are unchanged for now.

## Key points

- A lab contract that runs past mid-2028 could finish its term with Olyrian Diagnostics as the supplier.
- The diagnostics unit is about one in five Siemens Healthineers employees, so the separation means building standalone functions, which is a bigger job than putting up a new logo.

On November 5, Siemens Healthineers announced that the carve-out of its diagnostics business was under way. The unit will be rebranded as Olyrian Diagnostics. According to Reuters, it runs more than 16 billion tests each year, and the company expects to finish the separation by mid-2028.

Siemens Healthineers will become Healthineers, and the two rebrands will run side by side. Reuters reporters Kira Britten and Paolo Laudani described the Olyrian rebrand as a step ahead of a future divestment of the unit.

That leaves a practical question for lab directors and the procurement leads who sign reagent and service agreements for Siemens Healthineers analyzers, automation lines and point-of-care devices: what changes, and when? For now the answer is nothing. Clinical Lab Products reported that, as of the announcement, products and services, contracts, service levels and customer points of contact all stay the same, and that the company will tell customers directly about any future changes as the carve-out moves forward.

## A 140-year-old lab business gets its own name

Olyrian has a long history behind it. According to Clinical Lab Products, Siemens Healthineers put together its in vitro diagnostics unit through three acquisitions made in 2006 and 2007, and the roots of those companies go back as far as 1884. Among the milestones cited in the announcement are the first urine test strip for diabetes and the first analyzer in the industry to combine clinical chemistry and immunoassay testing in one automated, integrated system. Today the portfolio covers laboratory automation, informatics and point-of-care testing solutions, and the company says its assays address nearly every major disease area.

Olyrian will sell diagnostics for lab and point-of-care testing, a range the company says covers everything from patient draw to population health. The company says its purpose is to power human potential at the heart of care. It links that goal to two things: an exclusive focus on in vitro diagnostics, and pairing intelligent technology with the know-how of the people who produce, interpret and act on diagnostic information.

Sharon Bracken, head of diagnostics at Siemens Healthineers, presented the new name as the start of the business's next phase. In the release, she said the laboratory sits at the heart of care, and that each day the business helps care teams deliver the critical answers patients need. "Olyrian Diagnostics is how we'll define our next chapter," she said. The company says a dedicated brand will position the unit as one of the largest standalone companies focused only on diagnostics.

For a lab buyer, that "singular focus" language describes a supplier whose whole business would be the analyzers, assays and informatics the lab already runs. Today those products sit alongside imaging and therapy lines inside a broader medtech group.

Block Field

The workforce number tells you what kind of job this is. When one in five employees sits in the unit being separated, the company has to build standalone functions alongside the new brand. The sources don't say how many roles move or where. Still, the scale could help explain why the separation is not expected to finish until mid-2028.

## A double separation, and the contracts that outlast it

The rename is one layer of a wider restructuring, and the separation runs in two directions at once. The Wall Street Journal's Adrià Calatayud reported that the parent is dropping Siemens from its name as it advances toward a spinoff from its own parent group. In 2025, Siemens laid out plans to deconsolidate Healthineers by spinning off a 30% stake to shareholders.

At the same time, Healthineers is carving out its diagnostics unit, a rebrand the Journal described as the first step toward establishing a standalone company. The Olyrian name will arrive in stages rather than on a single date. So a lab buying from Siemens Healthineers today is dealing with a company that is stepping away from its own parent while also separating out the very unit the lab buys from.

Contract timing is where this hits lab operations. A lab contract that runs past mid-2028 could finish its term with Olyrian Diagnostics as the supplier. For labs about to sign longer agreements, the timeline is worth putting on the table during negotiation, since the company has said future changes will be communicated as they happen.

Block Field

## Margins, savings and stranded costs

Reuters set out the numbers behind the decision. In the fourth quarter, the diagnostics unit's adjusted EBIT margin came in at 5.4%, and its transformation program aims to deliver another 400 million euros (about $450 million) in savings. On the analyst call, CFO Jochen Schmitz said the business will keep working toward mid-teens margins over the medium term. Reuters linked recent pressure on the unit to market conditions in China after healthcare reforms there, and the company forecast slower-than-expected group growth for fiscal 2027.

Schmitz added that splitting off the unit would bring carve-out and stranded costs in the near term. Over the longer term, he said, the result would be a more focused business. Deutsche Bank described the quarterly results as "disappointing" but called the decision to separate the diagnostics business "sensible".

Put those statements side by side and the order of events is clear. Getting from a 5.4% quarterly margin to mid-teens would mean more than doubling it, and the separation adds its own costs before the focus pays off. Deutsche Bank's split verdict suggests at least one analyst house is weighing that longer-term focus more heavily than the weak quarter.

One reasonable worry is that a savings program running alongside a separation could squeeze customer support. The evidence doesn't point that way so far. The company has said in writing that service levels are unchanged, and a standalone diagnostics company would depend on its installed base of labs more than its current parent does. Even so, lab procurement leads can fairly ask how the 400 million euro program touches field service and applications support during the transition.

## The ultrasound exit as a reference point

Radiology Business editor Hannah Murphy reported that on October 12 the company stopped all sales of its general imaging ultrasound systems: the Acuson Sequoia, Redwood, Juniper and Maple. It still sells procedural products, including the Acuson Origin cardiovascular platform, the P500 intracardiac echocardiography system and the Freestyle system, along with software and catheters. Cardiovascular Business described the shift as a focus on equipment used by electrophysiologists and interventional cardiologists.

Sourabh Pagaria, head of Ultrasound, explained the move this way: "Medicine is evolving, and imaging is increasingly becoming part of therapy, not just diagnosis." The company said general imaging ultrasound is a market well served by multiple established providers. It expects procedural imaging, particularly electrophysiology and structural heart work where demand for image guidance has grown, to offer more long-term growth as minimally invasive treatments gain ground in cardiovascular care.

It also said that leaving the segment reflects a narrower business focus rather than an end to support for its installed base. That idea of narrowing links the two moves. Ultrasound narrowed toward procedures. Diagnostics is becoming a company whose stated purpose rests on a singular focus on in vitro diagnostics.

For existing ultrasound customers, the company committed to maintenance, software updates, transducer availability, and meeting contractual and regulatory obligations for the life of the systems. That is the clearest recent example of how Healthineers words its promises to an installed base when its portfolio changes. The two cases differ in one important way, though. Ultrasound was an exit from selling a product line. Olyrian will keep selling the whole diagnostics portfolio under a new structure, so the ultrasound terms show the kind of language to expect, not what will happen.

Block Field

The first real signs will be the staged arrival of the Olyrian name and whatever the company sends customers directly about contracts as the separation moves forward. As of the announcement, the company says there is no change to products, contracts, service levels or customer points of contact.

## Sources

- [Siemens Healthineers Starts Carve-Out of Diagnostics Business as Olyrian Diagnostics](https://clpmag.com/lab-management/company-news/siemens-healthineers-carve-diagnostics-olyrian/)
- [Siemens Healthineers begins carve-out of diagnostics unit ...](https://www.reuters.com/business/healthcare-pharmaceuticals/siemens-healthineers-starts-carve-out-diagnostics-business-2026-11-05/) (Reuters)
- [Siemens Healthineers to Rebrand as ...](https://www.wsj.com/business/siemens-healthineers-to-rebrand-as-healthineers-as-diagnostics-carve-out-begins-979c6b0b) (The Wall Street Journal)
- [Siemens Healthineers is stopping all sales of its general ...](https://radiologybusiness.com/topics/medical-imaging/ultrasound-imaging/siemens-healthineers-stopping-all-sales-its-general-ultrasound-systems) (Radiology Business)
- [News Alert: Siemens Healthineers doubles down on ...](https://cardiovascularbusiness.com/newsletter/2026-10-12/news-alert-siemens-healthineers-doubles-down-cardiovascular-care-it-exits-general-imaging-ultrasound) (Cardiovascular Business)
- [Datar Cancer Genetics Unveils Advanced Blood Test for MRD | Clinical Lab Products](https://clpmag.com/diagnostic-technologies/molecular-diagnostics/sequencing-systems/datar-cancer-genetics-unveils-advanced-blood-test-for-mrd/)

Tags: Siemens Healthineers, Olyrian Diagnostics, Healthineers, in vitro diagnostics, clinical laboratory, lab procurement, point-of-care testing, medtech carve-out, service contracts, healthcare supply chain, ultrasound

---
Source: MarketScale, https://www.marketscale.com/industries/healthcare/siemens-healthineers-begins-separating-its-16-billion-test-lab-business-into-olyrian-diagnostics. Published for AI indexing and citation; cite the canonical URL. Site guide for agents: https://www.marketscale.com/llms.txt
